Men’s Health Australia | Interview with Professor Eric Chung
LTR Pharma Scientific and Clinical Advisor and consultant urological surgeon, Professor Eric Chung was recently interviewed by Cayle Reid at Men’s Health Australia to discuss
Quarterly Activities Report and 4C – period ended 31 March 2024
LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024. Key highlights
SPONTAN® pivotal clinical study completes recruitment and dosing
LTR Pharma has today announced that all patients recruited for its pivotal bioequivalence clinical study of SPONTAN® nasal spray have now received their second and
Ausbiz | Interview with Lee Rodne
This week, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with Juliette Saly from ausbiz to discuss the Company’s progress in the advancement of rapid treatment
First patients dosed for SPONTAN® bioequivalence clinical study
LTR Pharma is pleased to announce the commencement of patient dosing in the Company’s pivotal bioequivalence clinical study of SPONTAN® nasal spray. The clinical study
ASX:LTP Half Year Financial Report
LTR Pharma has today released its Half Year Financial Report for the period ended 31 December 2023. This has been a defining period for the